Scholarlink

<p>A novel series of 1,2,4-triazole–benzoxazepine hybrid derivatives was designed, synthesized, and biologically evaluated as α-glucosidase inhibitors using an in vitro enzyme inhibition assay with acarbose as a reference standard. Several compounds demonstrated significant inhibitory activity, with compound <b>14</b> emerging as the most potent inhibitor (IC₅₀ = 49.26 µM), surpassing acarbose by approximately 3.6-fold, while compound <b>28</b> also showed notable activity (IC₅₀ = 72.14 µM). Structure–activity relationship analysis revealed that halogen substitution, particularly at the ortho position, plays a critical role in enhancing inhibitory potency. Molecular docking studies (PDB ID: 7KB6) provided mechanistic insights into ligand–enzyme interactions, showing that the most active compounds establish key π–π stacking interactions with residues TRP423, TRP525, and PHE307, along with π-anion interactions involving ASP640 and ASP564, and extensive hydrophobic contacts with PHE571, PHE673, MET565, and ARG624. Additionally, water-mediated hydrogen bonding (e.g., HOH1356, HOH1625) helps stabilize the ligand within the active site. These interactions enable simultaneous engagement of the catalytic active site and peripheral regions, supporting strong binding affinity. Overall, these results define clear structure–activity relationships and identify 1,2,4-triazole–benzoxazepine hybrids as promising lead scaffolds for further optimization toward novel antidiabetic agents.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Synthesis and structure–activity relationship studies of 1,2,4-triazole–benzoxazepine hybrids as α-glucosidase inhibitors: molecular docking and biological evaluation

  • 期刊论文

  • 发表日期：

    2026年4月28日

查看全文
  • Muhammad Ashram,
  • Ahmed Al-Mustafa,
  • Almeqdad Y. Habashneh,
  • Hamza I. Al-Hrerat,
  • Mahmoud A. Al-Sha’er,
  • Firas F. Awwadi,
  • Islam Ashram

摘要

A novel series of 1,2,4-triazole–benzoxazepine hybrid derivatives was designed, synthesized, and biologically evaluated as α-glucosidase inhibitors using an in vitro enzyme inhibition assay with acarbose as a reference standard. Several compounds demonstrated significant inhibitory activity, with compound 14 emerging as the most potent inhibitor (IC₅₀ = 49.26 µM), surpassing acarbose by approximately 3.6-fold, while compound 28 also showed notable activity (IC₅₀ = 72.14 µM). Structure–activity relationship analysis revealed that halogen substitution, particularly at the ortho position, plays a critical role in enhancing inhibitory potency. Molecular docking studies (PDB ID: 7KB6) provided mechanistic insights into ligand–enzyme interactions, showing that the most active compounds establish key π–π stacking interactions with residues TRP423, TRP525, and PHE307, along with π-anion interactions involving ASP640 and ASP564, and extensive hydrophobic contacts with PHE571, PHE673, MET565, and ARG624. Additionally, water-mediated hydrogen bonding (e.g., HOH1356, HOH1625) helps stabilize the ligand within the active site. These interactions enable simultaneous engagement of the catalytic active site and peripheral regions, supporting strong binding affinity. Overall, these results define clear structure–activity relationships and identify 1,2,4-triazole–benzoxazepine hybrids as promising lead scaffolds for further optimization toward novel antidiabetic agents.